Regulus Therapeutics
RGLS
#7200
Rank
ยฃ0.43 B
Marketcap
ยฃ6.24
Share price
0.00%
Change (1 day)
436.78%
Change (1 year)

Earnings for Regulus Therapeutics (RGLS)

Earnings in 2025 (TTM): -ยฃ36.82 Million

According to Regulus Therapeutics's latest financial reports the company's current earnings are N/A. In 2024 the company made an earning of -ยฃ35.31 Million a decrease over its 2023 earnings that were of -ยฃ22.5 Million. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Regulus Therapeutics from 2012 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) -ยฃ36.82 Million4.27%
2024 -ยฃ35.31 Million56.97%
2023 -ยฃ22.5 Million6.51%
2022 -ยฃ21.12 Million2.53%
2021 -ยฃ20.6 Million93.59%
2020 -ยฃ10.64 Million-15.41%
2019 -ยฃ12.58 Million-64.46%
2018 -ยฃ35.39 Million-33.26%
2017 -ยฃ53.02 Million-13.98%
2016 -ยฃ61.64 Million44.77%
2015 -ยฃ42.58 Million-1.63%
2014 -ยฃ43.29 Million203.6%
2013 -ยฃ14.26 Million8.65%
2012 -ยฃ13.13 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Sanofi
SNY
ยฃ5.95 B-16,520.40%๐Ÿ‡ซ๐Ÿ‡ท France
Biogen
BIIB
ยฃ0.34 B-1,038.46%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
ยฃ8.65 B-23,992.56%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
ยฃ11.53 B-31,913.87%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
ยฃ5.46 B-15,184.59%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sangamo Therapeutics
SGMO
-ยฃ84.31 Million 132.60%๐Ÿ‡บ๐Ÿ‡ธ USA
Dicerna Pharmaceuticals
DRNA
-ยฃ89.91 Million 148.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Alnylam Pharmaceuticals
ALNY
ยฃ0.93 B-2,675.32%๐Ÿ‡บ๐Ÿ‡ธ USA